TP53 and breast carcinoma: Ren et al. (2025) identified biallelic alterations in BRCA1, BRCA2, RAD51C, RAD51D, PPP2R2A, and TP53 as key HRD drivers in Asian cohorts of ovarian and breast cancers, enhancing therapeutic response prediction [5].